Companies
Shanghai Institute of Phage
established in 2017, it was the first institution in China to obtain qualification for clinical bacteriophage treatment and launched the country's first ethically approved phage-therapy clinical trial in 2018,…
- Country
- China
Research
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Affiliation | Shanghai Public Health Clinical Center, Fudan University | cphage.com · doi.org · frontiersin.org |
| Founded | 2017 | cphage.com · doi.org |
| Research focus | clinical bacteriophage therapy, drug-resistant bacterial infections, phage pharmacology, and synthetic phage design | cphage.com · doi.org |
| Principal staff | Tongyu Zhu, Xiaokui Guo, and Li-Kuang Chen (founders) | cphage.com · doi.org |
| Facility | Zhongshan Hospital of Fudan University (associated/partner for GMP facility and clinical trials) | doi.org · the-microbiologist.com · transplantation.com.cn |
Independent sources: cphage.com · doi.org · frontiersin.org · the-microbiologist.com · transplantation.com.cn
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bacteriophage therapy | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.